MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

MB-105 is a first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia ...

Houston-based March Biosciences, an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, announced that the US Food and Drug Administration (FDA ...

It is possible that AtLP represent multiclonal B cells, T cells or NK-cell lymphoproliferative processes in which there is an existence of occult abnormal B-cell, T-cell or NK-cell clones.

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies. Methods ...

Cell signalling is the mechanism by which stimuli are transmitted via a signalling cascade to effector molecules that orchestrate the appropriate response. Types of cell signalling pathways ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...

Molson Coors Beverage Co. Cl A 0.00% $11.14B Molson Coors Beverage Co. Cl B-3.12% $11.67B ...